Drimva

Xaira Therapeutics

Scientist II, High Throughput Biology

$124K–$155K

South San Francisco, California, United States · Full-time · Posted Sep 14, 2026

Experience
2–4 years of postdoctoral or industry experience; recent Ph.D. graduates or candidates with fewer years of experience are also encouraged to apply, and job level can be adjusted.
Education
Ph.D. in Immunology, Molecular Biology, Cell Biology, Biochemistry, Functional Genomics, or related field.

About the job

Designs and optimizes high-throughput experiments and screening workflows to support drug discovery, including binder discovery in mammalian systems.

What you'll do

  • Design, implement, and optimize biochemical, molecular, and cell-based assays for high-throughput screening.
  • Scale binder-discovery screening in mammalian systems and develop automated workflows that support data quality and reproducibility.
  • Pilot emerging technologies and collaborate with drug discovery, computational biology, and AI-based protein design teams to interpret screening data.

What they ask for

  • Ph.D. in Immunology, Molecular Biology, Cell Biology, Biochemistry, Functional Genomics, or a related field.
  • Proficiency in molecular biology techniques, complex library construction, flow cytometry, and cell line engineering.
  • Experience with pooled screening and NGS-based readouts, including library preparation and sequencing QC.
  • Strong analytical and data-analysis skills, including visualization and statistical software.

Nice to have

  • Experience with high-throughput antibody display technologies, including yeast, phage, or mammalian display.
  • Familiarity with single-cell genomics workflows, such as scRNA-seq, barcoded, or multiplexed assays.

Pay

$124,000 to $155,000 annually (base salary)

Tools

NGS, GraphPad Prism, R, Python, scRNA-seq, yeast display, phage display, mammalian display

AI focus

Collaborates with AI-based protein design teams to analyze and interpret screening data.

Model-written summary · the original posting is authoritative

First seen Oct 27, 2026 · Last verified Nov 6, 2026 (UTC)